Commonwealth of Pennsylvania Public School Empls Retrmt SYS Acquires 2,215 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) by 15.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,691 shares of the company’s stock after acquiring an additional 2,215 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in IDEXX Laboratories were worth $7,298,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Gray Wealth Management Inc. increased its holdings in shares of IDEXX Laboratories by 3.3% in the second quarter. Gray Wealth Management Inc. now owns 619 shares of the company’s stock valued at $311,000 after purchasing an additional 20 shares during the last quarter. Harbour Investments Inc. increased its holdings in shares of IDEXX Laboratories by 24.1% in the fourth quarter. Harbour Investments Inc. now owns 108 shares of the company’s stock valued at $44,000 after purchasing an additional 21 shares during the last quarter. American Trust increased its holdings in shares of IDEXX Laboratories by 5.1% in the second quarter. American Trust now owns 431 shares of the company’s stock valued at $216,000 after purchasing an additional 21 shares during the last quarter. KB Financial Partners LLC increased its holdings in shares of IDEXX Laboratories by 18.3% in the second quarter. KB Financial Partners LLC now owns 149 shares of the company’s stock valued at $75,000 after purchasing an additional 23 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of IDEXX Laboratories by 10.2% in the second quarter. EverSource Wealth Advisors LLC now owns 260 shares of the company’s stock valued at $131,000 after purchasing an additional 24 shares during the last quarter. 86.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on IDXX. JPMorgan Chase & Co. increased their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Piper Sandler cut IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price for the company. in a research note on Tuesday, January 30th. BNP Paribas started coverage on IDEXX Laboratories in a research note on Thursday, December 7th. They set an “outperform” rating and a $602.00 target price for the company. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. Finally, The Goldman Sachs Group raised their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $591.50.

View Our Latest Stock Report on IDXX

Insider Activity

In other news, CEO Jonathan Jay Mazelsky sold 7,128 shares of IDEXX Laboratories stock in a transaction on Monday, December 4th. The stock was sold at an average price of $513.05, for a total value of $3,657,020.40. Following the completion of the sale, the chief executive officer now directly owns 79,233 shares of the company’s stock, valued at $40,650,490.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the transaction, the chief financial officer now directly owns 29,718 shares in the company, valued at $16,939,557.18. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jonathan Jay Mazelsky sold 7,128 shares of IDEXX Laboratories stock in a transaction on Monday, December 4th. The shares were sold at an average price of $513.05, for a total value of $3,657,020.40. Following the completion of the transaction, the chief executive officer now owns 79,233 shares of the company’s stock, valued at $40,650,490.65. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,288 shares of company stock valued at $34,600,528. 2.11% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Trading Down 0.2 %

Shares of NASDAQ IDXX opened at $572.21 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $579.68. The company has a current ratio of 1.57, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The stock has a fifty day simple moving average of $540.92 and a 200-day simple moving average of $491.38. The stock has a market capitalization of $47.52 billion, a PE ratio of 56.82, a PEG ratio of 3.16 and a beta of 1.25.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last issued its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The business had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. During the same period in the previous year, the firm posted $2.05 earnings per share. The company’s revenue was up 8.8% on a year-over-year basis. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.13 earnings per share for the current year.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Further Reading

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.